Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma

Inclusion Criteria: * Histologically confirmed poorly differentiated or undifferentiated nasopharyngeal carcinoma (WHO type II and III) with distant metastasis (ie. other than loco-regional disease). Patients with stage IVc disease, ie. distant metastases on presentation are also eligible. * Have at least one measurable lesion according to RECIST which has not been irradiated. * WBC count ≥ 3 x 10\^9 /L with neutrophils ≥ 1.5 x 10\^9 /L, platelet count ≥ 100 x 10\^9 /L and Hb ≥ 9g/dL. * Serum creatinine ≤ 1.25 ULN * Be ambulatory and have a Karnofsky Performance Status of ≥ 70% at study entry. * Recover from prior radiotherapy prior to study entry * Effective contraception for both male and female if the risk of conception exists. * Able to swallow and retain oral medication. Exclusion Criteria: * Previous cytotoxic chemotherapy for recurrent or metastatic NPC. * Previous exposure to oxaliplatin and/or capecitabine. * Pregnant or lactating women. Women of childbearing potential with either positive or no pregnancy test at baseline. Women of childbearing potential not using a reliable and appropriate contraceptive method. (Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential) * Sexually active males unwilling to practice contraception during the study. * Clinically significant cardiac disease (eg. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months. * Patients with a history of central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake. * History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix. * Abnormal blood counts, AST, ALT, bilirubin and/or serum creatinine beyond the limits specified in the inclusion criteria. * Radiotherapy within 4 weeks of treatment start or prior radiotherapy to the indicator lesion(s) being measured in the study (newly arising marker lesions in previously irradiated areas are acceptable). * Major surgery within 4 weeks of the start of study treatment, without complete recovery. * Participation in any investigational drug study within 4 weeks preceding the start of treatment. * Symptomatic peripheral neuropathy NCI-CTCAE grade ≥ 2. * Known allergic/hypersensitivity reaction to any of the components of study treatments. * Serious uncontrolled intercurrent infections. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.